APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vector-Based RNAi

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Vector-Based RNAi Market Outlook and Growth Opportunities 2026

31 December 2025195 pages

Choose your research edition.

Industry ResearchVector-Based RNAi Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Vector-Based RNAi Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Vector-Based RNAi Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vector-Based RNAi Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Vector-Based RNAi Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Vector-Based RNAi market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vector-Based RNAi is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vector-Based RNAi is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vector-Based RNAi is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vector-Based RNAi market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vector-Based RNAi market include Alnylam Pharmaceuticals, Arcturus Therapeutics, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Ionis Pharmaceutical, Phio Pharmaceutical, Qiagen NV, Quark Pharmaceuticals and Silence Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vector-Based RNAi market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vector-Based RNAi and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vector-Based RNAi sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vector-Based RNAi market size, projected growth trends, production technologies, key applications, and end-use industries.

Vector-Based RNAi Segment by Company

Alnylam Pharmaceuticals

Arcturus Therapeutics

Arrowhead Pharmaceuticals

Dicerna Pharmaceuticals

Ionis Pharmaceutical

Phio Pharmaceutical

Qiagen NV

Quark Pharmaceuticals

Silence Therapeutics

Merck & Co.

Thermo Fisher Scientific

Vector-Based RNAi Segment by Type

Custom siRNA Construction

siRNA Vectors

siRNA Design

Vector-Based RNAi Segment by Application

Hospitals

Speciality Clinics

Vector-Based RNAi Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Vector-Based RNAi status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Vector-Based RNAi market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vector-Based RNAi significant trends, drivers, influence factors in global and regions.

6. To analyze Vector-Based RNAi competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vector-Based RNAi market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vector-Based RNAi and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vector-Based RNAi.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vector-Based RNAi market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vector-Based RNAi industry.

Chapter 3: Detailed analysis of Vector-Based RNAi manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Vector-Based RNAi in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Vector-Based RNAi in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vector-Based RNAi Industry Trends Table 2. Vector-Based RNAi Industry Drivers Table 3. Vector-Based RNAi Industry Opportunities and Challenges Table 4. Vector-Based RNAi Industry Restraints Table 5. Global Vector-Based RNAi Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vector-Based RNAi Revenue Share by Company (2021-2026) Table 7. Global Vector-Based RNAi Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Vector-Based RNAi Sales Volume Share by Company (2021-2026) Table 9. Global Vector-Based RNAi Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Vector-Based RNAi Company Ranking, (2024-2026) & (USD Million) Table 11. Global Vector-Based RNAi Key Company Manufacturing Base & Headquarters Table 12. Global Vector-Based RNAi Company, Product Type & Application Table 13. Global Vector-Based RNAi Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Vector-Based RNAi by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Custom siRNA Construction Table 18. Significant Companies of siRNA Vectors Table 19. Significant Companies of siRNA Design Table 20. Global Vector-Based RNAi Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Vector-Based RNAi Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Vector-Based RNAi Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Vector-Based RNAi Sales Volume Share by Type (2021-2026) Table 24. Global Vector-Based RNAi Sales Volume Share by Type (2027-2032) Table 25. Global Vector-Based RNAi Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Vector-Based RNAi Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Vector-Based RNAi Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Vector-Based RNAi Sales Value Share by Type (2021-2026) Table 29. Global Vector-Based RNAi Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospitals Table 31. Significant Companies of Speciality Clinics Table 32. Global Vector-Based RNAi Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Vector-Based RNAi Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Vector-Based RNAi Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Vector-Based RNAi Sales Volume Share by Application (2021-2026) Table 36. Global Vector-Based RNAi Sales Volume Share by Application (2027-2032) Table 37. Global Vector-Based RNAi Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Vector-Based RNAi Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Vector-Based RNAi Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Vector-Based RNAi Sales Value Share by Application (2021-2026) Table 41. Global Vector-Based RNAi Sales Value Share by Application (2027-2032) Table 42. Global Vector-Based RNAi Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Vector-Based RNAi Sales by Region (2021-2026) & (K Units) Table 44. Global Vector-Based RNAi Sales Market Share by Region (2021-2026) Table 45. Global Vector-Based RNAi Sales by Region (2027-2032) & (K Units) Table 46. Global Vector-Based RNAi Sales Market Share by Region (2027-2032) Table 47. Global Vector-Based RNAi Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Vector-Based RNAi Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Vector-Based RNAi Sales Value Share by Region (2021-2026) Table 50. Global Vector-Based RNAi Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Vector-Based RNAi Sales Value Share by Region (2027-2032) Table 52. Global Vector-Based RNAi Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Vector-Based RNAi Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Vector-Based RNAi Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Vector-Based RNAi Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Vector-Based RNAi Sales by Country (2021-2026) & (K Units) Table 57. Global Vector-Based RNAi Sales Market Share by Country (2021-2026) Table 58. Global Vector-Based RNAi Sales by Country (2027-2032) & (K Units) Table 59. Global Vector-Based RNAi Sales Market Share by Country (2027-2032) Table 60. Global Vector-Based RNAi Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Vector-Based RNAi Sales Value Market Share by Country (2021-2026) Table 62. Global Vector-Based RNAi Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Vector-Based RNAi Sales Value Market Share by Country (2027-2032) Table 64. Alnylam Pharmaceuticals Company Information Table 65. Alnylam Pharmaceuticals Business Overview Table 66. Alnylam Pharmaceuticals Vector-Based RNAi Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Alnylam Pharmaceuticals Vector-Based RNAi Product Portfolio Table 68. Alnylam Pharmaceuticals Recent Development Table 69. Arcturus Therapeutics Company Information Table 70. Arcturus Therapeutics Business Overview Table 71. Arcturus Therapeutics Vector-Based RNAi Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Arcturus Therapeutics Vector-Based RNAi Product Portfolio Table 73. Arcturus Therapeutics Recent Development Table 74. Arrowhead Pharmaceuticals Company Information Table 75. Arrowhead Pharmaceuticals Business Overview Table 76. Arrowhead Pharmaceuticals Vector-Based RNAi Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Arrowhead Pharmaceuticals Vector-Based RNAi Product Portfolio Table 78. Arrowhead Pharmaceuticals Recent Development Table 79. Dicerna Pharmaceuticals Company Information Table 80. Dicerna Pharmaceuticals Business Overview Table 81. Dicerna Pharmaceuticals Vector-Based RNAi Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Dicerna Pharmaceuticals Vector-Based RNAi Product Portfolio Table 83. Dicerna Pharmaceuticals Recent Development Table 84. Ionis Pharmaceutical Company Information Table 85. Ionis Pharmaceutical Business Overview Table 86. Ionis Pharmaceutical Vector-Based RNAi Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Ionis Pharmaceutical Vector-Based RNAi Product Portfolio Table 88. Ionis Pharmaceutical Recent Development Table 89. Phio Pharmaceutical Company Information Table 90. Phio Pharmaceutical Business Overview Table 91. Phio Pharmaceutical Vector-Based RNAi Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Phio Pharmaceutical Vector-Based RNAi Product Portfolio Table 93. Phio Pharmaceutical Recent Development Table 94. Qiagen NV Company Information Table 95. Qiagen NV Business Overview Table 96. Qiagen NV Vector-Based RNAi Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Qiagen NV Vector-Based RNAi Product Portfolio Table 98. Qiagen NV Recent Development Table 99. Quark Pharmaceuticals Company Information Table 100. Quark Pharmaceuticals Business Overview Table 101. Quark Pharmaceuticals Vector-Based RNAi Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Quark Pharmaceuticals Vector-Based RNAi Product Portfolio Table 103. Quark Pharmaceuticals Recent Development Table 104. Silence Therapeutics Company Information Table 105. Silence Therapeutics Business Overview Table 106. Silence Therapeutics Vector-Based RNAi Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Silence Therapeutics Vector-Based RNAi Product Portfolio Table 108. Silence Therapeutics Recent Development Table 109. Merck & Co. Company Information Table 110. Merck & Co. Business Overview Table 111. Merck & Co. Vector-Based RNAi Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Merck & Co. Vector-Based RNAi Product Portfolio Table 113. Merck & Co. Recent Development Table 114. Thermo Fisher Scientific Company Information Table 115. Thermo Fisher Scientific Business Overview Table 116. Thermo Fisher Scientific Vector-Based RNAi Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Thermo Fisher Scientific Vector-Based RNAi Product Portfolio Table 118. Thermo Fisher Scientific Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Vector-Based RNAi Distributors List Table 122. Vector-Based RNAi Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Vector-Based RNAi Product Image Figure 2. Global Vector-Based RNAi Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vector-Based RNAi Sales Value (2021-2032) & (US$ Million) Figure 4. Global Vector-Based RNAi Sales (2021-2032) & (K Units) Figure 5. Global Vector-Based RNAi Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Vector-Based RNAi Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Custom siRNA Construction Image Figure 10. siRNA Vectors Image Figure 11. siRNA Design Image Figure 12. Global Vector-Based RNAi Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Vector-Based RNAi Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Vector-Based RNAi Sales Volume Share by Type (2021-2032) Figure 15. Global Vector-Based RNAi Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Vector-Based RNAi Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Vector-Based RNAi Sales Value Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Speciality Clinics Image Figure 20. Global Vector-Based RNAi Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Vector-Based RNAi Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Vector-Based RNAi Sales Volume Share by Application (2021-2032) Figure 23. Global Vector-Based RNAi Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Vector-Based RNAi Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Vector-Based RNAi Sales Value Share by Application (2021-2032) Figure 26. Global Vector-Based RNAi Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Vector-Based RNAi Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Vector-Based RNAi Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Vector-Based RNAi Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Vector-Based RNAi Sales Value (2021-2032) & (US$ Million) Figure 31. North America Vector-Based RNAi Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Vector-Based RNAi Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Vector-Based RNAi Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Vector-Based RNAi Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Vector-Based RNAi Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Vector-Based RNAi Sales Value (2021-2032) & (US$ Million) Figure 37. South America Vector-Based RNAi Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Vector-Based RNAi Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Vector-Based RNAi Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Vector-Based RNAi Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Vector-Based RNAi Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Vector-Based RNAi Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Custom siRNA Construction
  • siRNA Vectors
  • siRNA Design
Applications
  • Hospitals
  • Speciality Clinics
Companies covered
  • Alnylam Pharmaceuticals
  • Arcturus Therapeutics
  • Arrowhead Pharmaceuticals
  • Dicerna Pharmaceuticals
  • Ionis Pharmaceutical
  • Phio Pharmaceutical
  • Qiagen NV
  • Quark Pharmaceuticals
  • Silence Therapeutics
  • Merck & Co.
  • Thermo Fisher Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vector-Based RNAi Sales Value (2021-2032)
  4. 1.2.2 Global Vector-Based RNAi Sales Volume (2021-2032)
  5. 1.2.3 Global Vector-Based RNAi Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Vector-Based RNAi Market Dynamics
  1. 2.1 Vector-Based RNAi Industry Trends
  2. 2.2 Vector-Based RNAi Industry Drivers
  3. 2.3 Vector-Based RNAi Industry Opportunities and Challenges
  4. 2.4 Vector-Based RNAi Industry Restraints
3 Vector-Based RNAi Market by Company
  1. 3.1 Global Vector-Based RNAi Company Revenue Ranking in 2025
  2. 3.2 Global Vector-Based RNAi Revenue by Company (2021-2026)
  3. 3.3 Global Vector-Based RNAi Sales Volume by Company (2021-2026)
  4. 3.4 Global Vector-Based RNAi Average Price by Company (2021-2026)
  5. 3.5 Global Vector-Based RNAi Company Ranking (2024-2026)
  6. 3.6 Global Vector-Based RNAi Company Manufacturing Base and Headquarters
  7. 3.7 Global Vector-Based RNAi Company Product Type and Application
  8. 3.8 Global Vector-Based RNAi Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Vector-Based RNAi Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Vector-Based RNAi Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Vector-Based RNAi Market by Type
  1. 4.1 Vector-Based RNAi Type Introduction
  2. 4.1.1 Custom siRNA Construction
  3. 4.1.2 siRNA Vectors
  4. 4.1.3 siRNA Design
  5. 4.2 Global Vector-Based RNAi Sales Volume by Type
  6. 4.2.1 Global Vector-Based RNAi Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Vector-Based RNAi Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Vector-Based RNAi Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Vector-Based RNAi Sales Value by Type
  10. 4.3.1 Global Vector-Based RNAi Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Vector-Based RNAi Sales Value by Type (2021-2032)
  12. 4.3.3 Global Vector-Based RNAi Sales Value Share by Type (2021-2032)
5 Vector-Based RNAi Market by Application
  1. 5.1 Vector-Based RNAi Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Speciality Clinics
  4. 5.2 Global Vector-Based RNAi Sales Volume by Application
  5. 5.2.1 Global Vector-Based RNAi Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Vector-Based RNAi Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Vector-Based RNAi Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Vector-Based RNAi Sales Value by Application
  9. 5.3.1 Global Vector-Based RNAi Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Vector-Based RNAi Sales Value by Application (2021-2032)
  11. 5.3.3 Global Vector-Based RNAi Sales Value Share by Application (2021-2032)
6 Vector-Based RNAi Regional Sales and Value Analysis
  1. 6.1 Global Vector-Based RNAi Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vector-Based RNAi Sales by Region (2021-2032)
  3. 6.2.1 Global Vector-Based RNAi Sales by Region: 2021-2026
  4. 6.2.2 Global Vector-Based RNAi Sales by Region (2027-2032)
  5. 6.3 Global Vector-Based RNAi Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Vector-Based RNAi Sales Value by Region (2021-2032)
  7. 6.4.1 Global Vector-Based RNAi Sales Value by Region: 2021-2026
  8. 6.4.2 Global Vector-Based RNAi Sales Value by Region (2027-2032)
  9. 6.5 Global Vector-Based RNAi Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Vector-Based RNAi Sales Value (2021-2032)
  12. 6.6.2 North America Vector-Based RNAi Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Vector-Based RNAi Sales Value (2021-2032)
  15. 6.7.2 Europe Vector-Based RNAi Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Vector-Based RNAi Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Vector-Based RNAi Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Vector-Based RNAi Sales Value (2021-2032)
  21. 6.9.2 South America Vector-Based RNAi Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Vector-Based RNAi Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Vector-Based RNAi Sales Value Share by Country, 2025 VS 2032
7 Vector-Based RNAi Country-level Sales and Value Analysis
  1. 7.1 Global Vector-Based RNAi Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vector-Based RNAi Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Vector-Based RNAi Sales by Country (2021-2032)
  4. 7.3.1 Global Vector-Based RNAi Sales by Country (2021-2026)
  5. 7.3.2 Global Vector-Based RNAi Sales by Country (2027-2032)
  6. 7.4 Global Vector-Based RNAi Sales Value by Country (2021-2032)
  7. 7.4.1 Global Vector-Based RNAi Sales Value by Country (2021-2026)
  8. 7.4.2 Global Vector-Based RNAi Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Vector-Based RNAi Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Vector-Based RNAi Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Vector-Based RNAi Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alnylam Pharmaceuticals
  2. 8.1.1 Alnylam Pharmaceuticals Company Information
  3. 8.1.2 Alnylam Pharmaceuticals Business Overview
  4. 8.1.3 Alnylam Pharmaceuticals Vector-Based RNAi Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Alnylam Pharmaceuticals Vector-Based RNAi Product Portfolio
  6. 8.1.5 Alnylam Pharmaceuticals Recent Developments
  7. 8.2 Arcturus Therapeutics
  8. 8.2.1 Arcturus Therapeutics Company Information
  9. 8.2.2 Arcturus Therapeutics Business Overview
  10. 8.2.3 Arcturus Therapeutics Vector-Based RNAi Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Arcturus Therapeutics Vector-Based RNAi Product Portfolio
  12. 8.2.5 Arcturus Therapeutics Recent Developments
  13. 8.3 Arrowhead Pharmaceuticals
  14. 8.3.1 Arrowhead Pharmaceuticals Company Information
  15. 8.3.2 Arrowhead Pharmaceuticals Business Overview
  16. 8.3.3 Arrowhead Pharmaceuticals Vector-Based RNAi Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Arrowhead Pharmaceuticals Vector-Based RNAi Product Portfolio
  18. 8.3.5 Arrowhead Pharmaceuticals Recent Developments
  19. 8.4 Dicerna Pharmaceuticals
  20. 8.4.1 Dicerna Pharmaceuticals Company Information
  21. 8.4.2 Dicerna Pharmaceuticals Business Overview
  22. 8.4.3 Dicerna Pharmaceuticals Vector-Based RNAi Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Dicerna Pharmaceuticals Vector-Based RNAi Product Portfolio
  24. 8.4.5 Dicerna Pharmaceuticals Recent Developments
  25. 8.5 Ionis Pharmaceutical
  26. 8.5.1 Ionis Pharmaceutical Company Information
  27. 8.5.2 Ionis Pharmaceutical Business Overview
  28. 8.5.3 Ionis Pharmaceutical Vector-Based RNAi Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Ionis Pharmaceutical Vector-Based RNAi Product Portfolio
  30. 8.5.5 Ionis Pharmaceutical Recent Developments
  31. 8.6 Phio Pharmaceutical
  32. 8.6.1 Phio Pharmaceutical Company Information
  33. 8.6.2 Phio Pharmaceutical Business Overview
  34. 8.6.3 Phio Pharmaceutical Vector-Based RNAi Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Phio Pharmaceutical Vector-Based RNAi Product Portfolio
  36. 8.6.5 Phio Pharmaceutical Recent Developments
  37. 8.7 Qiagen NV
  38. 8.7.1 Qiagen NV Company Information
  39. 8.7.2 Qiagen NV Business Overview
  40. 8.7.3 Qiagen NV Vector-Based RNAi Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Qiagen NV Vector-Based RNAi Product Portfolio
  42. 8.7.5 Qiagen NV Recent Developments
  43. 8.8 Quark Pharmaceuticals
  44. 8.8.1 Quark Pharmaceuticals Company Information
  45. 8.8.2 Quark Pharmaceuticals Business Overview
  46. 8.8.3 Quark Pharmaceuticals Vector-Based RNAi Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Quark Pharmaceuticals Vector-Based RNAi Product Portfolio
  48. 8.8.5 Quark Pharmaceuticals Recent Developments
  49. 8.9 Silence Therapeutics
  50. 8.9.1 Silence Therapeutics Company Information
  51. 8.9.2 Silence Therapeutics Business Overview
  52. 8.9.3 Silence Therapeutics Vector-Based RNAi Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Silence Therapeutics Vector-Based RNAi Product Portfolio
  54. 8.9.5 Silence Therapeutics Recent Developments
  55. 8.10 Merck & Co.
  56. 8.10.1 Merck & Co. Company Information
  57. 8.10.2 Merck & Co. Business Overview
  58. 8.10.3 Merck & Co. Vector-Based RNAi Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Merck & Co. Vector-Based RNAi Product Portfolio
  60. 8.10.5 Merck & Co. Recent Developments
  61. 8.11 Thermo Fisher Scientific
  62. 8.11.1 Thermo Fisher Scientific Company Information
  63. 8.11.2 Thermo Fisher Scientific Business Overview
  64. 8.11.3 Thermo Fisher Scientific Vector-Based RNAi Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Thermo Fisher Scientific Vector-Based RNAi Product Portfolio
  66. 8.11.5 Thermo Fisher Scientific Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vector-Based RNAi Value Chain Analysis
  2. 9.1.1 Vector-Based RNAi Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vector-Based RNAi Sales Mode & Process
  6. 9.2 Vector-Based RNAi Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vector-Based RNAi Distributors
  9. 9.2.3 Vector-Based RNAi Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst